Scholarlink

Background and aims <p>This study aimed to evaluate the efficacy of intravenous (IV) parecoxib in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis and clinically significant post-ERCP abdominal pain in patients undergoing their first ERCP.</p> Methods <p>Participants undergoing ERCP with a native papilla were randomly assigned to receive intravenous parecoxib plus standard IV fluid or standard IV fluid alone. Data on patient characteristics, initial serum bilirubin levels, procedural techniques, papilla type, and endoscopic risk factors were collected. The incidence rates of post-ERCP pancreatitis, hyperamylasemia, and post-ERCP abdominal pain were compared between the groups.</p> Results <p>A total of 83 and 82 patients were included in the parecoxib and control groups, respectively. There were no significant between-group differences in comorbidities, pre-procedure risks, or baseline laboratory results. The most common diagnosis after ERCP was bile duct stones (62%). The incidence of post-ERCP pancreatitis was 2.4% in the parecoxib group and 11.0% in the control group (<i>p</i> = 0.058). The incidence of post-ERCP abdominal pain was significantly lower in the parecoxib group than in the control group at both 4&#xa0;h (26.5% vs. 52.4%, <i>p</i> = 0.001) and 24&#xa0;h (6.0% vs. 20.7%, <i>p</i> = 0.011) after the procedure<b>.</b></p> Conclusions <p>Intravenous parecoxib was effective in reducing post-ERCP abdominal pain and showed a trend toward a lower incidence of post-ERCP pancreatitis (PEP) in both unselected and high-risk patients, without any serious adverse events. Therefore, intravenous parecoxib may represent a viable alternative for PEP prevention in settings where rectal nonsteroidal anti-inflammatory drugs are unavailable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of intravenous parecoxib in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月23日

查看全文
  • Thanaput Kunlayawutipong,
  • Tummarong Charoenrit,
  • Tanawat Jongraksak,
  • Thanawin Wong,
  • Nisa Netinatsunton,
  • Siriboon Attasaranya,
  • Thanapon Yaowmaneerat,
  • Jaksin Sottisuporn,
  • Suraphon Assawasuwannakit,
  • Siwanon Nawalerspanya,
  • Surawitch Sawathanon,
  • Pimsiri Sripongpun,
  • Tanawat Pattarapuntakul

摘要

Background and aims

This study aimed to evaluate the efficacy of intravenous (IV) parecoxib in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis and clinically significant post-ERCP abdominal pain in patients undergoing their first ERCP.

Methods

Participants undergoing ERCP with a native papilla were randomly assigned to receive intravenous parecoxib plus standard IV fluid or standard IV fluid alone. Data on patient characteristics, initial serum bilirubin levels, procedural techniques, papilla type, and endoscopic risk factors were collected. The incidence rates of post-ERCP pancreatitis, hyperamylasemia, and post-ERCP abdominal pain were compared between the groups.

Results

A total of 83 and 82 patients were included in the parecoxib and control groups, respectively. There were no significant between-group differences in comorbidities, pre-procedure risks, or baseline laboratory results. The most common diagnosis after ERCP was bile duct stones (62%). The incidence of post-ERCP pancreatitis was 2.4% in the parecoxib group and 11.0% in the control group (p = 0.058). The incidence of post-ERCP abdominal pain was significantly lower in the parecoxib group than in the control group at both 4 h (26.5% vs. 52.4%, p = 0.001) and 24 h (6.0% vs. 20.7%, p = 0.011) after the procedure.

Conclusions

Intravenous parecoxib was effective in reducing post-ERCP abdominal pain and showed a trend toward a lower incidence of post-ERCP pancreatitis (PEP) in both unselected and high-risk patients, without any serious adverse events. Therefore, intravenous parecoxib may represent a viable alternative for PEP prevention in settings where rectal nonsteroidal anti-inflammatory drugs are unavailable.